{
    "nctId": "NCT02415387",
    "briefTitle": "Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer",
    "officialTitle": "The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 172,
    "primaryOutcomeMeasure": "AUC Change in Level of IL-6",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-10 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors)\n* All women will be postmenopausal\n\nExclusion Criteria:\n\n* A prior history of any other malignancy except basal or squamous cell skin cancers, strokes, diabetes, current heart disease or uncontrolled hypertension, peripheral vascular disease, liver disease, autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis, and other medical conditions that would limit participation in the assessments (e.g., pulmonary disease, orthopedic problems, major psychiatric illness, major cognitive dysfunction, or an acute medical problem)\n* Anemia\n* Alcohol or drug abuse\n* Smoking\n* Medication exclusions will include steroids as well as statins and other medications with anti-inflammatory actions\n* Women who have received a typhoid vaccine within the last three years",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}